Updated March 31 at 10:09pm

Amgen partners with French pharmaceuticals company

Biotechnology company Amgen Inc., which has a manufacturing plant in West Greenwich, and France-based pharmaceuticals company Servier announced a collaboration agreement that allows the exchange of rights to various cardiovascular disease therapies between the two companies. More

To continue reading this article, please do one of the following.



Sign up to receive Providence Business News' newsletters
and breaking news alerts.  

biotechnology

Amgen partners with French pharmaceuticals company

Posted:

THOUSAND OAKS, Calif. – Biotechnology company Amgen Inc., which has a manufacturing plant in West Greenwich, and France-based pharmaceuticals company Servier announced a collaboration agreement that allows the exchange of rights to various cardiovascular disease therapies between the two companies.

Through the collaboration Amgen has gained commercial rights in the U.S. to Servier’s oral drug treatment for chronic heart failure, ivabradine or Procoralan in the EU. The company has also gained rights to commercialize a Servier molecule that is currently in development for cardiovascular diseases.

“Amgen is pleased to enter into this collaboration with Servier to bring potential new cardiovascular treatment options to patients in both the U.S. and Europe,” Amgen’s Executive Vice President of Research and Development Dr. Sean E. Harper said in a statement. “Ivabradine, an ifinhibitor, offers a novel alternative approach for patients with elevated heart rates.”

Servier obtained rights to commercialize in Europe an activator that is being tested to treat heart failure in patients with systolic dysfunction

Amgen will make an upfront payment of $50 million to Servier. It will also make payments for future royalties for ivabradine.

“Servier is very pleased to establish a collaboration with Amgen,” said Dr. Jean-Philippe Seta, CEO of Servier, in a statement. “This is a clear recognition of the medical value of ivabradine, one of our major cardiovascular innovations, which could also benefit U.S. patients.”

amgen, servier, biotechnology

Comments

No comments on this story | Please log in to comment by clicking here
Please log in or register to add your comment
Latest News